Physician profile
Gregory W Smith
NPI 1225007842
$45,830.98
in general payments reported to CMS, 2019-2025
55 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $2,619 · 2021: $4,361 · 2022: $1,321 · 2023: $6,782 · 2024: $4,393 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,731 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,856.37 |
| Food and Beverage | $2,731.10 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,259.43 | 2019-2021 | |
| Immunogen, INC. | $5,940.59 | 2023 | Elahere |
| Incyte Corporation | $5,075.75 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Rigel Pharmaceuticals, INC. | $4,514.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,638.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,983.38 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $2,733.97 | 2021-2024 | Ojjaara, Jemperli |
| Janssen Biotech, INC. | $2,177.91 | 2019-2025 | Rybrevant, Carvykti |
| Amgen INC. | $1,382.67 | 2019-2024 | Lumakras |
| Verastem, INC. | $1,331.38 | 2019-2020 | |
| Genentech USA, INC. | $709.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $667.18 | 2019-2023 | Reblozyl |
| Acceleron Pharma, INC. | $650.00 | 2021 | |
| Array Biopharma INC | $600.00 | 2019 | |
| Pfizer INC. | $412.79 | 2019-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.